NCT02219672

Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir of Chinese HIV/AIDS Patients In Acute HIV-1 Infection

Status unknown Phase 3 Last updated 18 August 2014

What this trial tests

Phase 3 trial testing Triplitode in AIDS/HIV PROBLEM in 18 participants. Status unknown.

Timeline

1 July 2014

Primary endpoint
1 July 2016

1 July 2017

Quick facts

Lead sponsor	Peking Union Medical College
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	prevention
Enrollment	18
Start date	1 July 2014
Primary completion	1 July 2016
Estimated completion	1 July 2017
Sites	1 location across China

Drugs / interventions tested

• Triplitode — full drug profile →
• Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir — full drug profile →

Conditions studied

• AIDS/HIV PROBLEM — all drugs for AIDS/HIV PROBLEM →

Sponsor

Peking Union Medical College

Who can join

Adults 18 to 65, any sex, with AIDS/HIV PROBLEM. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Changes of the immunologic response, virologic response, and hiv-1 reservoir
  Time frame: baseline and at Week 4, Week 12, Week 24, Week 36 follow-up visits

Sponsor's own description

This study is a prospective trial which will recruit 18 patients in acute HIV-1 infection phase. This study aims to evaluate the effects and side effects of ARV treatment in Chinese patients in acute HIV-1 infection phase, and to evaluate the impact of Triptolide wilfordii on HIV-1 reservoir.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Block-And-Lock Strategies to Cure HIV Infection.
   Vansant G, Bruggemans A, Janssens J, Debyser Z. · · 2020 · cited 125× · PMID 31936859 · DOI 10.3390/v12010084
2. Targeting HIV transcription: the quest for a functional cure.
   Mousseau G, Mediouni S, Valente ST. · · 2015 · cited 63× · PMID 25731772 · DOI 10.1007/82_2015_435
3. The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders.
   Mediouni S, Marcondes MC, Miller C, McLaughlin JP, et al · · 2015 · cited 49× · PMID 26557111 · DOI 10.3389/fmicb.2015.01164
4. Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.
   Jean MJ, Fiches G, Hayashi T, Zhu J. · · 2019 · cited 23× · PMID 30351168 · DOI 10.1089/aid.2018.0153
5. Didehydro-Cortistatin A: a new player in HIV-therapy?
   Mousseau G, Valente ST. · · 2016 · cited 22× · PMID 26581953 · DOI 10.1586/14787210.2016.1122525
6. Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.
   Jin H, Li D, Lin MH, Li L, et al · · 2020 · cited 21× · PMID 32276443 · DOI 10.3390/v12040415
7. Forging a Functional Cure for HIV: Transcription Regulators and Inhibitors.
   Mediouni S, Lyu S, Schader SM, Valente ST. · · 2022 · cited 19× · PMID 36146786 · DOI 10.3390/v14091980
8. Fighting HIV-1 Persistence: At the Crossroads of "Shoc-K and B-Lock".
   Acchioni C, Palermo E, Sandini S, Acchioni M, et al · · 2021 · cited 14× · PMID 34832672 · DOI 10.3390/pathogens10111517